MD Anderson Cancer Center
Test helps identify glioblastoma patients most likely to benefit from drug
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
Video is loading...
Title: Test helps identify glioblastoma patients most likely to benefit from drug
Summary: A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
Keywords: extComm, Communications - External
Transcript: